Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-L1 t-haNK in Locally Advanced or Metastatic Solid Cancers
NCT04050709Phase 1Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of PD-L1 t-haNK in solid tumor (4 arms), sponsored by ImmunityBio, Inc. Primary endpoints: Maximum Tolerated Dose or Highest Tolerated Dose and Recommended Phase 2 Dose at 1 year and Incidence of Dose-Limiting Toxicities and Treatment-Emergent Adverse Events at 1 year. Started Jul 2019; status: completed.
02
Drugs
PD-L1 t-haNK
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04050709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050709.